This two-part series led by Sarah A. Holstein, MD, PhD, and Ashley E. Rosko, MD, will explore expert perspectives on practice-changing developments in the management of multiple myeloma and will also include updates from the 2021 American Society of Hematology (ASH) Annual Meeting & Exposition.

Part 1 of this series will take an in-depth look at the new standards in multiple myeloma classification at diagnosis, recent data on treatment regimens for newly diagnosed disease, and strategies for maintenance therapy. Start the activity now!

This two-part series led by Sarah A. Holstein, MD, PhD, and Ashley E. Rosko, MD, will explore expert perspectives on practice-changing developments in the management of multiple myeloma and will also include updates from the 2021 American Society of Hematology (ASH) Annual Meeting & Exposition.

Part 2 will familiarize practitioners with indications of multiple myeloma progression and timing of therapy, highlight practice-changing trials in the early and late relapse settings, and discuss how approaches to relapsed/refractory multiple myeloma are changing based on emerging data. Start the activity now!

Discover new developments in the management of metastatic squamous non–small cell lung cancer (NSCLC), including individualized care plans, efficacy and safety of novel therapies, and strategies to optimize survivorship for patients with NSCLC. This activity is presented by expert faculty, Mark G. Kris, MD, Memorial Sloan Kettering Cancer Center, and Victoria Sherry, DNP, CRNP, AOCNP®, Nurse Practitioner, Abramson Cancer Center. Start the activity now. 

Presented by Amir Fathi, MD, Associate Professor of Medicine at Harvard Medical School, this activity will highlight individualized treatment selection for patients with acute lymphoblastic leukemia (ALL), as well as recent efficacy and safety data for novel therapeutic strategies. Start the activity now.

This in-depth discussion, presented by Louis Diehl, MD, Professor of Medicine at Duke University Medical School, will feature strategies for incorporating predictive and prognostic markers, recent efficacy and safety data, and adverse event management strategies into treatment selection for patients with Hodgkin lymphoma (HL). Start the activity now.

Discover insights on predictive and prognostic markers, emerging efficacy and safety data, strategies to optimize tolerability for patients receiving novel therapies for mantle cell lymphoma (MCL), and more in this case-based activity presented by John Leonard, MD, the Richard T. Silver Distinguished Professor of Hematology and Medical Oncology at Weill Cornell Medicine. Start the activity now.

This activity, presented by Mikkael Sekeres, MD, Chief of the Division of Hematology at the University of Miami Health System, will focus on predictive and prognostic markers for myelodysplastic syndromes (MDS), emerging data on novel therapies, and strategies to optimize safety and tolerability for patients with this disease. Start the activity now.

In this case-based discussion, Morie Gertz, MD, Chair of General Internal Medicine at the Mayo Clinic in Minnesota, will discuss how to use predictive and prognostic markers to select treatment for patients with Waldenstrom macroglobulinemia (WM) and how to appraise emerging clinical trial data and adverse event management strategies for novel treatments. Start the activity now.